Mindpeak announces scanner agnostic CE-marked PD-L1 AI solution to support Lung Cancer Diagnosis
We at Mindpeak GmbH are very happy to announce the CE mark for our „Mindpeak Lung (NSCLC) PD-L1 (SP263) RoI“, a plug-and-play AI solution to detect and quantify PD-L1 expression within user-defined Regions of Interest (RoI) on non-small-cell lung cancer. In a study our software showed a 96.5% agreement for the most relevant scanners on the market. Mindpeak Lung PD-L1, our 7th CE marked product, is a milestone in supporting pathologists in the diagnosis of Lung Cancer, which is among the most difficult tasks for pathologists. It identifies tumorous cells and quantifies them to support TPS-scoring.
You may also be interested in
In a first of its kind comparative study, Mindpeak's CE-marked HER2 AI for breast cancer diagnosis was compared to three other commercial AIs (e.g. Visiopharm). Mindpeak's AI showed the highest accuracy of all AIs in terms of balanced clinical scores (88.1%) for HER2-low, higher than the score of the next best AI (67.3%) and higher than the concordance of pathologists with the reference score (85.5%).